ARDX - Latest News

Ardelyx, Inc. (ARDX), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $1.58B. Beta to the broader market is 0.61.

The article list below shows the most recent ARDX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent ARDX Headlines

Ardelyx: Low Price, But High Implied Valuation

seekingalpha.com - May 8, 2026

Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCE

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings

globenewswire.com - May 7, 2026

WALTHAM, Mass. , May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc.

Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript

seekingalpha.com - Apr 30, 2026

Ardelyx, Inc.

Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates

zacks.com - Apr 30, 2026

Ardelyx (ARDX) came out with a quarterly loss of $0. 15 per share versus the Zacks Consensus Estimate of a loss of $0.

Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics

zacks.com - Apr 30, 2026

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended March 2026, it could be wort

How News Affects ARDX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ARDX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked ARDX news questions

What is the latest ARDX news headline?

The most recent ARDX headline (May 8, 2026) is "Ardelyx: Low Price, But High Implied Valuation". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the ARDX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What ARDX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual ARDX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.